Dasatinib vs imatinib in the treatment of paediatric ALL

Bookmark and Share
Published: 24 Dec 2019
Views: 242
Rating:
Save
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China

Dr Shuhong Shen speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a study treating paediatric Acute Lymphoblastic Leukaemia.

This open-label phase III randomised study was conducted at 20 hospitals in China. Of the 225 patients with the diagnosis, 35 declined and 1 died before treatment.

Intensive chemotherapy including dasatinib at 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared to imatinib at 300 mg/m2 per day and provided excellent control of central-nervous-system leukaemia without the use of prophylactic cranial irradiation.